Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Francisco

Source: Oxurion NV

Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco.

Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s business and diabetic eye disease clinical pipeline at the Ophthalmology Innovation Summit (OIS) meeting, which will be held on October 10m 2019, at the Hilton San Francisco Union Square.

In his presentation, Dr. De Haes will focus on the prospects for Oxurion’s two VEGF-independent drug candidates, THR-149 and THR-687, which are being developed for diabetic macular edema (DME). THR-149 has recently completed a positive phase 1 study and Oxurion expects to announce results from an on-going phase 1 study with THR-687, a pan-RGD integrin antagonist, toward the end of 2019.

At the American Academy of Ophthalmology’s annual meeting (AAO), Arshad M. Khanani, MD, will present ‘A Phase 1, Open Label, Dose Escalation study of THR-149 for the Treatment of Diabetic Macular Edema (DME)’(poster presentation – P0455).

Topline data from the phase 1 study (n=12) evaluating THR-149 for treatment of DME show that THR-149 is well-tolerated and safe.

Study data also indicate that a single injection of THR-149 resulted in an immediate (day 1) positive impact on patient’s Best Corrected Visual Acuity (BCVA). This improvement continued with an average improvement in BCVA of up to 7.5 letters being achieved at Day 14. Importantly, this activity was also maintained with an average improvement in BCVA of 6.4 letters at the end of study (Day 90).

THR-149 has been developed with Bicycle Therapeutics. Oxurion holds the exclusive license to the PKal inhibitor portfolio originating from this partnership.

“We are pleased to have the opportunity to present the positive findings from our successful phase 1 study to the large number of retinal physicians attending both OIS and AAO,” Dr. De Haes, said in a news release. “The clinical profile of THR-149 holds potential for it to become a best-in-class PKal inhibitor for the treatment of DME. We are currently preparing a phase 2 study with multiple injections of THR-149, and we anticipate the first patient to be enrolled in early 2020.”

Oxurion will be welcoming visitors at booth #5123 in the AAO Exhibition Hall.

Related Content